Search

for
Search:

GlossaryRitlecitinib

investigational drug targeting enzymes involved in autoimmune hair loss

Ritlecitinib is an investigational drug that targets specific enzymes known as Janus kinases (JAKs) and TEC family kinases, which are involved in the immune response. It is being studied for its potential to treat autoimmune conditions like alopecia areata, where the immune system mistakenly attacks hair follicles, leading to hair loss.

Related Terms

Learn

0 / 0 results

— no results

Research

5 / 178 results

research A Phase 2a Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of the Oral Janus Kinase Inhibitors Ritlecitinib and Brepocitinib in Alopecia Areata: 24-Week Results

138 citations , March 2021 in “Journal of the American Academy of Dermatology”

Ritlecitinib and brepocitinib effectively regrow hair in alopecia areata patients.

research Evaluating the Therapeutic Potential of Ritlecitinib for the Treatment of Alopecia Areata

49 citations , February 2022 in “Drug Design Development and Therapy”

Ritlecitinib shows promise for hair regrowth in alopecia areata patients.

research Ritlecitinib And Brepocitinib Demonstrate Significant Improvement In Scalp Alopecia Areata Biomarkers

36 citations , December 2021 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology”

Two drugs, ritlecitinib and brepocitinib, improved scalp hair loss condition markers.

research Maintenance, Withdrawal, and Re-Treatment with Ritlecitinib and Brepocitinib in Patients with Alopecia Areata in a Single-Blind Extension of a Phase 2a Randomized Clinical Trial

20 citations , December 2021 in “Journal of the American Academy of Dermatology”

Continuous treatment with ritlecitinib and brepocitinib is needed to maintain hair regrowth in alopecia areata.

research Virtual Bioequivalence Assessment of Ritlecitinib Capsules with Incorporation of Observed Clinical Variability Using a Physiologically Based Pharmacokinetic Model

15 citations , January 2024 in “The AAPS Journal”

50-mg ritlecitinib capsules are bioequivalent to 100-mg capsules.

View more "ritlecitinib" in research →

Community Join

4 / 4 results

community Anyone else taking Litfulo (ritlecitinib) to treat their alopecia?

in Treatment 7 upvotes 2 years ago

A user diagnosed with Alopecia Areata started using Litfulo (ritlecitinib), kenalog shots, and mometasone furoate 0.1%. They shaved their head and are seeking others' experiences with Litfulo.

community Article of all potential future cures

in Treatment 25 upvotes 6 months ago

Ritlecitinib and PP405 show promise for hair regrowth. Diagnosing the cause of hair loss is crucial before treatment.

community Update July 2025] Most Promising Hair Loss Treatments in Clinical Trials

in Research/Science 265 upvotes 4 months ago

Promising hair loss treatments in clinical trials include Pyrilutamide, GT20029, CB-03-01, and PP405, with potential market releases between 2027 and 2029. Hair cloning remains experimental and expensive, while existing treatments like finasteride, minoxidil, and microneedling continue to be used.

community How do we only have two treatments to combat hair loss at this point in time?

in Chat 211 upvotes 2 years ago

The post discusses frustration over the limited and not always effective treatments for hair loss, mainly Minoxidil and Finasteride. The conversation includes mentions of potential new treatments like GT20029, HMI-115, CosmeRNA, KX-826, and microneedling, but also highlights the challenges of funding and prioritizing research in this area.